Bioventus (NYSE:BVS – Get Free Report) will be announcing its earnings results before the market opens on Tuesday, November 5th. Analysts expect the company to announce earnings of $0.06 per share for the quarter. Bioventus has set its FY 2024 guidance at 0.360-0.420 EPS.
Bioventus (NYSE:BVS – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.12. Bioventus had a negative net margin of 7.82% and a positive return on equity of 14.39%. The business had revenue of $151.22 million for the quarter, compared to analyst estimates of $137.70 million. During the same period in the prior year, the company posted $0.14 EPS. On average, analysts expect Bioventus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Bioventus Price Performance
Shares of Bioventus stock traded up $0.35 on Wednesday, hitting $13.66. The company’s stock had a trading volume of 98,684 shares, compared to its average volume of 387,385. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -20.70 and a beta of 0.90. Bioventus has a 1 year low of $3.36 and a 1 year high of $13.72. The company has a debt-to-equity ratio of 1.82, a quick ratio of 0.96 and a current ratio of 1.33. The firm has a fifty day moving average price of $11.35 and a 200-day moving average price of $8.01.
Insider Activity at Bioventus
Analysts Set New Price Targets
A number of research firms have recently commented on BVS. Craig Hallum boosted their price objective on Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, September 27th. Canaccord Genuity Group boosted their price target on shares of Bioventus from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, August 13th.
Get Our Latest Research Report on Bioventus
About Bioventus
Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.
See Also
- Five stocks we like better than Bioventus
- Using the MarketBeat Dividend Yield Calculator
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Canadian Penny Stocks: Can They Make You Rich?
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- What is the Australian Securities Exchange (ASX)
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.